Ims Health Holdings Inc. (IMS) 29.00 $IMS
4 Top-Rated Drugmakers Reporting Earnings This Week
at Investor's Business Daily - Sun Apr 26, 7:02AM CDT
This week will bring first-quarter earnings reports from four top-rated large-cap drug stocks, and each is expected to report strong growth. On Tuesday before the open, United Therapeutics (UTHR) is expected to report revenue of $353.5 million, up...
IMS: 29.00 (+1.02), VRX: 210.42 (+1.03), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), UTHR: 186.69 (-1.87), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)
IMS Health Holdings' (IMS) CEO Ari Bousbib on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Apr 24, 2:28PM CDT
IMS: 29.00 (+1.02)
IMS Health beats Street 1Q forecasts
Automated Insights - Fri Apr 24, 6:43AM CDT
DANBURY, Conn. (AP) _ IMS Health Holdings Inc. (IMS) on Friday reported first-quarter net income of $298 million, after reporting a loss in the same period a year earlier.
IMS: 29.00 (+1.02)
IMS Health beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 6:05AM CDT
IMS: 29.00 (+1.02)
IMS Health Reports First-Quarter 2015 Results
Business Wire - Fri Apr 24, 6:00AM CDT
--Adjusted EBITDA up 9.8 percent at constant currency
IMS: 29.00 (+1.02)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 4:30PM CDT
BIIB: 401.71 (-28.57), SPG: 188.71 (-0.35), B: 41.02 (+0.56), INFY: 31.81 (-3.15), VTR: 72.82 (-0.24), AOS: 66.59 (+0.94), LYB: 100.83 (+3.26), COG: 33.03 (+0.05), AJG: 49.06 (+1.30), AAL: 52.71 (+1.26), AAN: 32.80 (+3.43), AVX: 13.97 (-0.81), TYC: 40.04 (-2.55), STT: 76.36 (-1.83), FNFG: 8.86 (-0.15), IMGN: 9.96 (-0.29), IPG: 21.79 (+0.63), XRX: 11.99 (-1.15), DTE: 82.81 (-0.01), LEA: 115.08 (-0.97), FLIR: 30.53 (-0.38), IMS: 29.00 (+1.02), SHOO: 41.52 (+3.17), OFG: 14.81 (-1.06), AZN: 71.79 (-1.34), PB: 52.17 (-0.86), EHTH: 13.50 (+2.06)
IMS Health to Announce First-Quarter 2015 Results on April 24, 2015
Business Wire - Wed Apr 15, 3:15PM CDT
IMS Health Holdings, Inc. ("IMS Health"
(NYSE:IMS) will issue its first-quarter 2015 financial results before the market opens on Friday, April 24, 2015. The press release and accompanying financial information will be posted on the IMS Health Investor Relations website at http://ir.imshealth.com.
IMS: 29.00 (+1.02)
IMS Health Study: 2014 a Record-Setting Year for U.S. Medicines
Business Wire - Tue Apr 14, 11:14AM CDT
--Key Drivers Include Increased Demand for New Specialty Drugs, Record Number of Transformative Treatments, Fewer Patent Expiries
IMS: 29.00 (+1.02)
IMS Health Holdings: Cegedim Acquisition Completed - A Potential Source Of Upside
stockguru - at Seeking Alpha - Thu Apr 09, 1:59PM CDT
IMS: 29.00 (+1.02)
3 Events That Could Sink the Biotech Sector This Year
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Apr 05, 8:06AM CDT
The biotech sector has been hot over the last few years, which naturally leads to talk of a biotech bubble. We asked our healthcare experts for potential events that might pop that bubble -- or at least let a little air out. While we're certainly...
BLUE: 136.26 (-3.82), IMS: 29.00 (+1.02), ESRX: 87.34 (+0.45), GILD: 103.69 (-1.52), CLDN: 13.68 (-0.26), ABBV: 66.07 (+1.82)
IMS Health Completes Acquisition of Cegedim's CRM and Strategic Data Businesses
Business Wire - Wed Apr 01, 4:00PM CDT
IMS Health (NYSE:IMS), a leading global provider of information and technology services to the healthcare and life sciences industries, today completed its previously announced acquisition of certain customer relationship management (CRM) and strategic data businesses of Cegedim.
IMS: 29.00 (+1.02)
Karen Katen Joins IMS Health Board of Directors
Business Wire - Mon Mar 30, 3:51PM CDT
IMS Health (NYSE:IMS) announced the appointment of Karen Katen to its board of directors, effective today. A senior pharmaceutical industry executive at Pfizer for more than three decades, Karen retired in 2007 as vice chairman of Pfizer Inc. and president of Pfizer Human Health.
IMS: 29.00 (+1.02), PFE: 35.27 (-0.09)
IMS Health's Social Media Analytics Solution Named a Leader by IDC MarketScape
Business Wire - Fri Mar 27, 5:05PM CDT
IMS Health (NYSE:IMS) has been named a leader in IDC Health Insights' assessment of social media and analytics software and services offerings available to the life sciences industry. The report, IDC MarketScape: Worldwide Life Science Social Media Analytics 2014 Vendor Assessment (doc # HI252646, December 2014), names IMS Health as a leader for Nexxus(TM) Social, its best-in-class SaaS solution that monitors and integrates information from tens of millions of social media sources worldwide -- providing structure and insights that can be used by life sciences companies to inform key regulatory compliance and commercial decision-making processes.
IMS: 29.00 (+1.02)
IMS Health Study: Reimbursement Approaches Based on Cost-Per-Quality-Adjusted-Life-Year Measures Rather Than Drug Effectiveness May Limit Access to Innovative Cancer Treatments
Business Wire - Fri Mar 27, 4:55PM CDT
Even as the surge in innovative oncology medicines yields new therapeutic options for a growing number of cancer patients, different approaches to reimbursement by health systems across the globe are likely having an impact both on patient access to transformative treatments and overall care, according to a new report from the IMS Institute for Healthcare Informatics. In five countries examined where healthcare agencies adopt more rigid cost-effectiveness thresholds to determine reimbursement levels for oncology medicines, the study found that fewer new cancer drugs are being reimbursed, reimbursement decisions are taking longer and new cancer drugs are being adopted more slowly and at lower rates.
IMS: 29.00 (+1.02)
IMS Health prices debt offering
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 6:12AM CDT
IMS: 29.00 (+1.02)
IMS Health Announces Pricing of Senior Notes to Finance Proposed Acquisition of Cegedim's CRM and Strategic Data Businesses
Business Wire - Thu Mar 19, 5:44PM CDT
IMS Health Holdings, Inc. (NYSE:IMS) today announced the pricing of its offering of EUR275 million in gross proceeds of senior notes to be issued by its wholly-owned subsidiary, IMS Health Incorporated. The net proceeds from the notes offering will be used to fund a portion of the purchase price for IMS Health's previously announced proposed acquisition of certain customer relationship management and strategic data businesses of Cegedim, SA and for related fees and expenses.
IMS: 29.00 (+1.02)
IMS Health to float debt to pay for Cegedim assets
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 9:08AM CDT
IMS: 29.00 (+1.02)
IMS Health Announces Offering of Senior Notes to Finance Proposed Acquisition of Cegedim's CRM and Strategic Data Businesses
Business Wire - Mon Mar 16, 7:00AM CDT
IMS Health Holdings, Inc. (NYSE:IMS) today announced that its wholly-owned subsidiary, IMS Health Incorporated, intends to raise EUR275 million in gross proceeds through an offering of senior notes due 2023. The net proceeds from the notes offering will be used to fund a portion of the purchase price for IMS Health's previously announced proposed acquisition of certain customer relationship management and strategic data businesses of Cegedim, SA and for related fees and expenses. The consummation of the notes offering is subject to market and other conditions.
IMS: 29.00 (+1.02)
10 Rife Russell 1000 Dividend Dogs Do 9.42% To 32.35% March Upsides
Fredrik Arnold - at Seeking Alpha - Sun Mar 15, 2:03AM CDT
NYCB: 16.90 (-0.10), FCX: 20.82 (+0.75), AGNC: 21.58 (-0.02), RRD: 19.30 (-0.40), CLF: 6.03 (+0.47), SDRL: 11.39 (-0.26), WIN: 7.83 (-0.46), SRC: 11.80 (-0.02), STWD: 24.27 (+0.10), NLY: 10.25 (-0.01), IMS: 29.00 (+1.02), MFA: 7.96 (unch), CIM: 15.55 (+0.05), TWO: 10.66 (+0.02), LPT: 35.30 (-0.26), ARCP: 9.12 (-0.06), CTL: 36.41 (-0.25), NRF: 18.97 (+0.02)
Comparing America's Next 3 Information Technology Services Companies
Joseph Cafariello - at Seeking Alpha - Wed Mar 11, 10:49AM CDT
IMS: 29.00 (+1.02), NOW: 76.09 (-0.79), CSC: 65.56 (-0.09)
4 Top-Rated Drugmakers Reporting Earnings This Week
at Investor's Business Daily - Sun Apr 26, 7:02AM CDT
This week will bring first-quarter earnings reports from four top-rated large-cap drug stocks, and each is expected to report strong growth. On Tuesday before the open, United Therapeutics (UTHR) is expected to report revenue of $353.5 million, up...
IMS: 29.00 (+1.02), VRX: 210.42 (+1.03), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), UTHR: 186.69 (-1.87), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)
IMS Health Holdings' (IMS) CEO Ari Bousbib on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Apr 24, 2:28PM CDT
IMS: 29.00 (+1.02)
IMS Health beats Street 1Q forecasts
Automated Insights - Fri Apr 24, 6:43AM CDT
DANBURY, Conn. (AP) _ IMS Health Holdings Inc. (IMS) on Friday reported first-quarter net income of $298 million, after reporting a loss in the same period a year earlier.
IMS: 29.00 (+1.02)
IMS Health beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 6:05AM CDT
IMS: 29.00 (+1.02)
IMS Health Reports First-Quarter 2015 Results
Business Wire - Fri Apr 24, 6:00AM CDT
--Adjusted EBITDA up 9.8 percent at constant currency
IMS: 29.00 (+1.02)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 4:30PM CDT
BIIB: 401.71 (-28.57), SPG: 188.71 (-0.35), B: 41.02 (+0.56), INFY: 31.81 (-3.15), VTR: 72.82 (-0.24), AOS: 66.59 (+0.94), LYB: 100.83 (+3.26), COG: 33.03 (+0.05), AJG: 49.06 (+1.30), AAL: 52.71 (+1.26), AAN: 32.80 (+3.43), AVX: 13.97 (-0.81), TYC: 40.04 (-2.55), STT: 76.36 (-1.83), FNFG: 8.86 (-0.15), IMGN: 9.96 (-0.29), IPG: 21.79 (+0.63), XRX: 11.99 (-1.15), DTE: 82.81 (-0.01), LEA: 115.08 (-0.97), FLIR: 30.53 (-0.38), IMS: 29.00 (+1.02), SHOO: 41.52 (+3.17), OFG: 14.81 (-1.06), AZN: 71.79 (-1.34), PB: 52.17 (-0.86), EHTH: 13.50 (+2.06)
IMS Health to Announce First-Quarter 2015 Results on April 24, 2015
Business Wire - Wed Apr 15, 3:15PM CDT
IMS Health Holdings, Inc. ("IMS Health"
(NYSE:IMS) will issue its first-quarter 2015 financial results before the market opens on Friday, April 24, 2015. The press release and accompanying financial information will be posted on the IMS Health Investor Relations website at http://ir.imshealth.com. IMS: 29.00 (+1.02)
IMS Health Study: 2014 a Record-Setting Year for U.S. Medicines
Business Wire - Tue Apr 14, 11:14AM CDT
--Key Drivers Include Increased Demand for New Specialty Drugs, Record Number of Transformative Treatments, Fewer Patent Expiries
IMS: 29.00 (+1.02)
IMS Health Holdings: Cegedim Acquisition Completed - A Potential Source Of Upside
stockguru - at Seeking Alpha - Thu Apr 09, 1:59PM CDT
IMS: 29.00 (+1.02)
3 Events That Could Sink the Biotech Sector This Year
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Apr 05, 8:06AM CDT
The biotech sector has been hot over the last few years, which naturally leads to talk of a biotech bubble. We asked our healthcare experts for potential events that might pop that bubble -- or at least let a little air out. While we're certainly...
BLUE: 136.26 (-3.82), IMS: 29.00 (+1.02), ESRX: 87.34 (+0.45), GILD: 103.69 (-1.52), CLDN: 13.68 (-0.26), ABBV: 66.07 (+1.82)
IMS Health Completes Acquisition of Cegedim's CRM and Strategic Data Businesses
Business Wire - Wed Apr 01, 4:00PM CDT
IMS Health (NYSE:IMS), a leading global provider of information and technology services to the healthcare and life sciences industries, today completed its previously announced acquisition of certain customer relationship management (CRM) and strategic data businesses of Cegedim.
IMS: 29.00 (+1.02)
Karen Katen Joins IMS Health Board of Directors
Business Wire - Mon Mar 30, 3:51PM CDT
IMS Health (NYSE:IMS) announced the appointment of Karen Katen to its board of directors, effective today. A senior pharmaceutical industry executive at Pfizer for more than three decades, Karen retired in 2007 as vice chairman of Pfizer Inc. and president of Pfizer Human Health.
IMS: 29.00 (+1.02), PFE: 35.27 (-0.09)
IMS Health's Social Media Analytics Solution Named a Leader by IDC MarketScape
Business Wire - Fri Mar 27, 5:05PM CDT
IMS Health (NYSE:IMS) has been named a leader in IDC Health Insights' assessment of social media and analytics software and services offerings available to the life sciences industry. The report, IDC MarketScape: Worldwide Life Science Social Media Analytics 2014 Vendor Assessment (doc # HI252646, December 2014), names IMS Health as a leader for Nexxus(TM) Social, its best-in-class SaaS solution that monitors and integrates information from tens of millions of social media sources worldwide -- providing structure and insights that can be used by life sciences companies to inform key regulatory compliance and commercial decision-making processes.
IMS: 29.00 (+1.02)
IMS Health Study: Reimbursement Approaches Based on Cost-Per-Quality-Adjusted-Life-Year Measures Rather Than Drug Effectiveness May Limit Access to Innovative Cancer Treatments
Business Wire - Fri Mar 27, 4:55PM CDT
Even as the surge in innovative oncology medicines yields new therapeutic options for a growing number of cancer patients, different approaches to reimbursement by health systems across the globe are likely having an impact both on patient access to transformative treatments and overall care, according to a new report from the IMS Institute for Healthcare Informatics. In five countries examined where healthcare agencies adopt more rigid cost-effectiveness thresholds to determine reimbursement levels for oncology medicines, the study found that fewer new cancer drugs are being reimbursed, reimbursement decisions are taking longer and new cancer drugs are being adopted more slowly and at lower rates.
IMS: 29.00 (+1.02)
IMS Health prices debt offering
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 6:12AM CDT
IMS: 29.00 (+1.02)
IMS Health Announces Pricing of Senior Notes to Finance Proposed Acquisition of Cegedim's CRM and Strategic Data Businesses
Business Wire - Thu Mar 19, 5:44PM CDT
IMS Health Holdings, Inc. (NYSE:IMS) today announced the pricing of its offering of EUR275 million in gross proceeds of senior notes to be issued by its wholly-owned subsidiary, IMS Health Incorporated. The net proceeds from the notes offering will be used to fund a portion of the purchase price for IMS Health's previously announced proposed acquisition of certain customer relationship management and strategic data businesses of Cegedim, SA and for related fees and expenses.
IMS: 29.00 (+1.02)
IMS Health to float debt to pay for Cegedim assets
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 9:08AM CDT
IMS: 29.00 (+1.02)
IMS Health Announces Offering of Senior Notes to Finance Proposed Acquisition of Cegedim's CRM and Strategic Data Businesses
Business Wire - Mon Mar 16, 7:00AM CDT
IMS Health Holdings, Inc. (NYSE:IMS) today announced that its wholly-owned subsidiary, IMS Health Incorporated, intends to raise EUR275 million in gross proceeds through an offering of senior notes due 2023. The net proceeds from the notes offering will be used to fund a portion of the purchase price for IMS Health's previously announced proposed acquisition of certain customer relationship management and strategic data businesses of Cegedim, SA and for related fees and expenses. The consummation of the notes offering is subject to market and other conditions.
IMS: 29.00 (+1.02)
10 Rife Russell 1000 Dividend Dogs Do 9.42% To 32.35% March Upsides
Fredrik Arnold - at Seeking Alpha - Sun Mar 15, 2:03AM CDT
NYCB: 16.90 (-0.10), FCX: 20.82 (+0.75), AGNC: 21.58 (-0.02), RRD: 19.30 (-0.40), CLF: 6.03 (+0.47), SDRL: 11.39 (-0.26), WIN: 7.83 (-0.46), SRC: 11.80 (-0.02), STWD: 24.27 (+0.10), NLY: 10.25 (-0.01), IMS: 29.00 (+1.02), MFA: 7.96 (unch), CIM: 15.55 (+0.05), TWO: 10.66 (+0.02), LPT: 35.30 (-0.26), ARCP: 9.12 (-0.06), CTL: 36.41 (-0.25), NRF: 18.97 (+0.02)
Comparing America's Next 3 Information Technology Services Companies
Joseph Cafariello - at Seeking Alpha - Wed Mar 11, 10:49AM CDT
IMS: 29.00 (+1.02), NOW: 76.09 (-0.79), CSC: 65.56 (-0.09)
